PeptiDream uses its proprietary drug discovery platform PDPS to expand strategic partnerships aimed at acquiring new technologies beyond its existing joint research activities. It currently has joint research agreements with 17 companies worldwide, including major pharmaceutical companies, and has increased partnerships aimed at acquiring new technologies since 2016.
PeptiDream uses PDPS, a platform for synthesizing specialized peptides that contain unnatural amino acids, and has conducted numerous joint research and development projects in which peptides that act on specific targets are transferred to other companies. It currently has joint research agreements with 17 companies worldwide, including major pharmaceutical companies.
Since 2016, these partnerships have shifted toward strategic alliances aimed at acquiring new technologies, and the company has been actively incorporating external technologies.
The article is structured around comments from Masuya Keiichi (舛屋圭一), Director and Head of Research and Development, on the current situation and future outlook.